Press Release

FOR IMMEDIATE RELEASE

Contacts:
Dr. Wayne Danter, President & CSO
519-858-5157
wdanter@criticaloutcome.com

Michael Barr, Director of Marketing & Business Development
519-858-5157
mbarr@criticaloutcome.com

CRITICAL OUTCOME TECHNOLOGIES INC. AND DDP THERAPEUTICS ANNOUNCE PROMISING PRELIMINARY TEST RESULTS FOR SMALL CELL LUNG CANCER MOLECULES

London, Ontario (January 24, 2007): Critical Outcome Technologies Inc. (TSX Venture: COT), through its interest in DDP Therapeutics (formerly 6441513 Canada Inc.), has received promising preliminary results regarding *in vitro* drug resistance in lung cancer cell lines for the first 3 small cell lung cancer lead molecules. The lead molecules were discovered and optimized by Critical Outcome Technologies Inc. (COTI). COTI has a 10% equity interest in DDP Therapeutics (DDP).

Small cell lung cancer (SCLC) represents approximately 20% of all lung cancers worldwide. DDP is addressing this unmet medical need by developing a library of low toxicity small molecules specifically designed for the oral treatment of SCLC. The first 3 compounds are nearing the end of pre-clinical development. As part of this pre-clinical development, DDP has just completed preliminary *in vitro* experiments designed to look for the development of resistance to the first 3 compounds compared with paclitaxel and cisplatin over successive generations of cell division and growth.

Typically SCLC is quite sensitive to initial chemotherapy. Unfortunately, resistance develops quickly to current paclitaxel and cisplatin based chemotherapeutic routines and once resistance develops subsequent survival is poor. In these preliminary experiments, none of the 3 lead compounds induced or selected for resistance in 2 representative human lung cancer cell lines (A549 and DMS153). In contrast, both paclitaxel and cisplatin did induce and/or select for early and significant resistance. Additional *in vitro* experiments using another human SCLC cell line (SHP-77) are currently in progress. The SHP-77 SCLC cell line was chosen because these cells are known to over express multi-drug resistant proteins. Experiments to determine if lack of induction of resistance by these 3 compounds (and induction of resistance by paclitaxel and cisplatin) is applicable to a broader range of different lung cell lines has not been done. While promising, these results should not be over interpreted to assume that this is the case in all lung tumor cell lines, nor do these results necessarily predict the behavior of compound treated (or paclitaxel or cisplatin-treated) primary tumors or xenografts *in vivo*. However, the treatment results to date using an animal model of human SCLC with HSP-77 tumors have been encouraging when the 3 compounds are compared directly with current best therapies.

Press Release

DDP Therapeutics is now seeking and evaluating partner candidates to out-license and advance the SCLC small molecule library through clinical trials.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development. For more information on COTI, please visit www.criticaloutcome.com